PGR and neoplasm: For women with a delay in their breast cancer diagnosis after recall, we found no significant trends over time or proportional fluctuations in tumour characteristics, surgical treatment or survival, except for a positive progesterone receptor status decreasing from 87.2% (1999–2003) to 64.6% (2009–2013, Supplementary Table S3).